Welcome to our dedicated page for Sana Biotechnology news (Ticker: $SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sana Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sana Biotechnology's position in the market.
Rhea-AI Summary
Sana Biotechnology, a company focused on engineered cells, announced the publication in Blood of initial clinical data from the ARDENT Phase 1 clinical trial with SC291, a hypoimmune (HIP)-modified allogeneic CD19-directed CAR T cell therapy. SC291 appeared safe and well tolerated, evaded immune detection, and induced a partial response in a patient with chronic lymphocytic leukemia (CLL). ARDENT is a Phase 1 study evaluating safety and tolerability of SC291 in patients with CLL and non-Hodgkin lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Sana Biotechnology, Inc. (SANA) will present at two investor conferences in November and December, featuring a business overview and update. The company will present at the 6th Annual Evercore ISI HealthCONx Conference on November 29, 2023, and at the JMP Securities Hematology and Oncology Summit on December 6, 2023. Webcasts will be accessible on Sana's Investor Relations page with replays available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.74%
Tags
-
Rhea-AI Summary
Sana Biotechnology, Inc. (NASDAQ: SANA) and Uppsala University Hospital in Sweden have announced the authorization of Uppsala University’s Clinical Trial Application (CTA) to initiate a first-in-human study of UP421, an allogeneic, primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, in patients with type 1 diabetes. The goal is to provide proof of concept for transplanting functional islet cells without immunosuppression. The study will focus on safety, cell survival, immune evasion, and C-peptide production. Insights from this study may inform the development of Sana’s SC451, a hypoimmune-modified stem-cell derived islet cell therapy for patients with type 1 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
Rhea-AI Summary
Sana Biotechnology, Inc. (NASDAQ: SANA) receives FDA clearance for Phase 1 trial of SC291, a CAR T cell therapy for multiple B-cell mediated autoimmune diseases. Initial clinical data expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
-
Rhea-AI Summary
Sana Biotechnology, Inc. (NASDAQ: SANA) reported financial results and business highlights for the third quarter 2023. The company is focusing on developing hypoimmune technology, with potential data from four clinical settings in 2023 and 2024. They are enrolling patients for Phase 1 ARDENT trial investigating SC291 in refractory B-cell malignancies, submitting CTA for IST evaluating HIP-modified primary islet cells in type 1 diabetes patients, and expecting proof of concept data for SC291 in multiple B-cell-mediated autoimmune diseases in 2024. Additionally, they are presenting multiple abstracts at the 2023 ASH Annual Meeting and have a cash position of $268.6 million expected to last into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
-
Rhea-AI Summary
Sana Biotechnology, Inc. announced that five abstracts will have poster presentations at the 65th American Society of Hematology Annual Meeting. The presentations will cover topics such as the treatment of large B cell lymphoma patients, genetic engineering of human hematopoietic stem progenitor cells, and the development of a novel CAR for multiple myeloma patients. The presentations will take place from December 9-12, 2023, in San Diego, CA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
Rhea-AI Summary
Sana Biotechnology announces increased focus on ex vivo cell therapy platform and IND submission for SC291 in autoimmune diseases
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.95%
Tags
-
Rhea-AI Summary
Sana Biotechnology to webcast presentations at five investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.77%
Tags
Sana Biotechnology, Inc.
Nasdaq:SANA
SANA Rankings
SANA Stock Data
2.21B
128.64M
9.16%
82.23%
11.85%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
SEATTLE
About SANA
sana biotechnology is focused on utilizing engineered cells as medicines for patients. the ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. sana is building differentiated capabilities across the spectrum of cell and gene therapy. three aspirations drive sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. the first is the ability to repair and control the genes in any cell in the body. we are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. last is a belief we can enable broader access to ou